Epigenetics in Prostate Cancer Treatment

Overview

Journal J Transl Genet Genom

Date 2022 Apr 4

PMID 35372800

Authors

Katelyn Jones

Yanquan Zhang

Yifan Kong

Elia Farah

Ruixin Wang

Chaohao Li

Xinyi Wang

Zhuangzhuang Zhang

Jianlin Wang

Fengyi Mao

Xiaoqi Liu

Jinghui Liu

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is the most commonly diagnosed malignancy among men, and the progression of this disease results in fewer treatment options available to clinical patients. It highlights the vital necessity for discovering novel therapeutic approaches and expanding the current understanding of molecular mechanisms. Epigenetic alternations such as DNA methylation models and histone modifications have been associated as key drivers in the development and advancement of PCa. Several studies have been conducted and demonstrated that targeting these epigenetic enzymes or regulatory proteins has been strongly associated with the regulation of cancer cell growth. Due to the success rate of these therapeutic routes in pre-clinical settings, many drugs have now advanced to clinical testing, where efficacy will be measured. This review will discuss the role of epigenetic modifications in PCa development and its function in the progression of the disease to resistant forms and introduce therapeutic strategies that have demonstrated successful results as PCa treatment.

Citing Articles

Prostate cancer detection through unbiased capture of methylated cell-free DNA.

Lleshi E, Milne-Clark T, Lee Yu H, Martin H, Hanson R, Lach R iScience. 2024; 27(7):110330.

PMID: 39055933 PMC: 11269940. DOI: 10.1016/j.isci.2024.110330.

Discovery of the First-in-Class G9a/GLP PROTAC Degrader.

Velez J, Han Y, Yim H, Yang P, Deng Z, Park K J Med Chem. 2024; 67(8):6397-6409.

PMID: 38602846 PMC: 11069390. DOI: 10.1021/acs.jmedchem.3c02394.

Discovery of the First-in-class G9a/GLP PROTAC Degrader.

Velez J, Han Y, Yim H, Yang P, Deng Z, Park K bioRxiv. 2024; .

PMID: 38464025 PMC: 10925177. DOI: 10.1101/2024.02.26.582210.

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

Zaalberg A, Pottendorfer E, Zwart W, Bergman A Cancers (Basel). 2024; 16(2).

PMID: 38254784 PMC: 10813511. DOI: 10.3390/cancers16020294.

Prostate cancer genetic risk and associated aggressive disease in men of African ancestry.

Soh P, Mmekwa N, Petersen D, Gheybi K, van Zyl S, Jiang J Nat Commun. 2023; 14(1):8037.

PMID: 38052806 PMC: 10697980. DOI: 10.1038/s41467-023-43726-w.

References

Shu S, Polyak K . BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harb Symp Quant Biol. 2017; 81:123-129. DOI: 10.1101/sqb.2016.81.030908. View

Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M . Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Res. 2017; 77(20):5564-5575. DOI: 10.1158/0008-5472.CAN-17-0314. View

Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C . Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression. Eur Urol. 2017; 72(5):835-844. PMC: 5802348. DOI: 10.1016/j.eururo.2017.04.005. View

Xia C, Tao Y, Li M, Che T, Qu J . Protein acetylation and deacetylation: An important regulatory modification in gene transcription (Review). Exp Ther Med. 2020; 20(4):2923-2940. PMC: 7444376. DOI: 10.3892/etm.2020.9073. View

Mukhopadhyay N, Kim J, You S, Morello M, Hager M, Huang W . Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2. Oncogene. 2013; 33(25):3235-45. PMC: 3934948. DOI: 10.1038/onc.2013.294. View

Robey R, Chakraborty A, Basseville A, Luchenko V, Bahr J, Zhan Z . Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm. 2011; 8(6):2021-31. PMC: 3230675. DOI: 10.1021/mp200329f. View

Kim J, Lee Y, Lu X, Song B, Fong K, Cao Q . Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator. Cell Rep. 2018; 25(10):2808-2820.e4. PMC: 6342284. DOI: 10.1016/j.celrep.2018.11.035. View

Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y . G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017; 8(1):274. PMC: 5561105. DOI: 10.1038/s41467-017-00350-9. View

HUGEL A, Wernert N . Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer. Br J Cancer. 1999; 79(3-4):551-7. PMC: 2362403. DOI: 10.1038/sj.bjc.6690087. View

10.

Wu Y, Li X, Yu J, Bjorkholm M, Xu D . ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells. Cell Death Dis. 2019; 10(2):76. PMC: 6349940. DOI: 10.1038/s41419-019-1357-z. View

11.

Lee J, Kim Y, Kim I, Kim B, Choi H, Lee J . Negative regulation of hypoxic responses via induced Reptin methylation. Mol Cell. 2010; 39(1):71-85. PMC: 4651011. DOI: 10.1016/j.molcel.2010.06.008. View

12.

Shi J, Cao J, Zhou B . Twist-BRD4 complex: potential drug target for basal-like breast cancer. Curr Pharm Des. 2014; 21(10):1256-61. PMC: 5644350. DOI: 10.2174/1381612821666141211153853. View

13.

Angulo J, Andres G, Ashour N, Sanchez-Chapado M, Lopez J, Ropero S . Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile. J Urol. 2015; 195(3):619-26. DOI: 10.1016/j.juro.2015.10.172. View

14.

Wang C, Chang J, Yan H, Wang D, Liu Y, Jing Y . A conserved RAD6-MDM2 ubiquitin ligase machinery targets histone chaperone ASF1A in tumorigenesis. Oncotarget. 2015; 6(30):29599-613. PMC: 4745749. DOI: 10.18632/oncotarget.5011. View

15.

Yang Z, Yik J, Chen R, He N, Jang M, Ozato K . Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005; 19(4):535-45. DOI: 10.1016/j.molcel.2005.06.029. View

16.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E . Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017; 61(2):462-481. PMC: 5788414. DOI: 10.1021/acs.jmedchem.6b01816. View

17.

Dutta A, Le Magnen C, Mitrofanova A, Ouyang X, Califano A, Abate-Shen C . Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. Science. 2016; 352(6293):1576-80. PMC: 5507586. DOI: 10.1126/science.aad9512. View

18.

Guler G, Tindell C, Pitti R, Wilson C, Nichols K, KaiWai Cheung T . Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure. Cancer Cell. 2017; 32(2):221-237.e13. DOI: 10.1016/j.ccell.2017.07.002. View

19.

Sanulli S, Justin N, Teissandier A, Ancelin K, Portoso M, Caron M . Jarid2 Methylation via the PRC2 Complex Regulates H3K27me3 Deposition during Cell Differentiation. Mol Cell. 2015; 57(5):769-783. PMC: 4352895. DOI: 10.1016/j.molcel.2014.12.020. View

20.

Hammerich-Hille S, Bardout V, Hilsenbeck S, Osborne C, Oesterreich S . Low SAFB levels are associated with worse outcome in breast cancer patients. Breast Cancer Res Treat. 2009; 121(2):503-9. DOI: 10.1007/s10549-008-0297-6. View